Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.48 - $29.82
Previous CloseN/A
Volume99.93K
Average Volume (3M)224.61K
Market Cap
$339.04M
Enterprise Value$284.66M
Total Cash (Recent Filing)$56.75M
Total Debt (Recent Filing)$59.97M
Price to Earnings (P/E)19.5
Beta2.56
Next Earnings
May 06, 2025EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.97
Shares Outstanding17,862,959
10 Day Avg. Volume224,034
30 Day Avg. Volume224,611
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.01
Price to Cash Flow (P/CF)6.20
P/FCF Ratio5.50
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.77
Enterprise Value/Ebitda10.18
Forecast
1Y Price Target
$39.00Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Rigel News
PremiumCompany Announcements
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board
PremiumCompany Announcements
Rigel Pharmaceuticals Reports Record Sales and Strategic Growth---
Bulls Say, Bears Say
Bulls Say
EarningsRigel Pharmaceuticals exceeded earnings expectations for both the fourth quarter and full year, indicating strong financial performance.
International ExpansionApproval from the Korean Ministry of Food and Drug Safety for Tavalisse boosts Rigel's presence in the international market.
Strategic PartnershipsRigel announced an exclusive license and supply agreement with Kissei Pharmaceuticals for the development and commercialization of Rezlidhia in Japan, the Republic of Korea, and Taiwan.
Bears Say
Safety ConcernsRigel announced the issuance of a Dear Health Care Provider letter regarding a new safety signal for Gavreto relating to increased risk of severe infections.
---
Ownership Overview
5.37% Insiders
25.89% Mutual Funds
22.35% Other Institutional Investors
35.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.48 and its highest was $29.82 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $339.04M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is May 06, 2025 which is in 39 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Mar 04, 2025. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.451 by $0.349.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.09.
How many shares outstanding does Rigel have?
Rigel has 17,862,959 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $0.8 in its last earnings report, beating expectations of $0.451. Following the earnings report the stock price went down -8.107%.
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
---
Rigel Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (105.48% Upside)
$39.00 (105.48% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 10.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $424.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.66%
12-Months-Change
Fundamentals
Return on Equity
531.78%
Trailing 12-Months
Asset Growth
320.74%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
---
RIGL Company Deck
---
RIGL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong year for Rigel Pharmaceuticals, marked by record-breaking sales, successful product integration, and global expansion. Despite some reliance on inventory build and pending decisions on study designs, the company's achievements in financial performance and R&D progress contribute to a predominantly positive outlook.Read More>---
RIGL Stock 12 Month Forecast
Average Price Target
$39.00
▲(105.48% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alkermes
―
BioMarin Pharmaceutical
―
Incyte
―
Vertex Pharmaceuticals
―
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
11/14 ratings generated profit
1 Year Average Return
+47.88%
reiterated a buy rating 24 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +47.88% per trade.
---